LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials).

Liwen Ye,Xixi Yang,Qingwei Chen,Jian Wang

doi:10.18632/oncotarget.22442

Abstract

BackgroundTo determine the effectiveness and safety of LCZ696 for the clinical treatment of hypertension, we performed a meta-analysis of the previous clinical trials.MethodsRelevant English articles and randomized controlled trials were searched in Pubmed, Embase, EBSCO, Cochrane base and ClinicalTrials.gov. The last search date was July 20th, 2017.ResultsCompared with 20mg olmesartan, 200mg and 400mg LCZ696 outperformed olmesartan in terms of reducing mean sitting systolic blood pressure, mean ambulatory systolic blood pressure, mean sitting diastolic blood pressure and mean ambulatory diastolic blood pressure. Compared with 20mg olmesartan, 200mg and 400mg LCZ696 was better than olmesartan in terms of reducing mean sitting pulse pressure. And these studies showed that 400mg LCZ696 was better than 20mg olmesartan in terms of reducing mean ambulatory pulse pressure, however, there was no significant difference between 200mg LCZ696 and 20mg olmesartan in terms of redducing mean ambulatory pulse pressure. In addition, 200mg and 400mg LCZ696 was better than placebo in terms of reducing blood pressure parameters mentioned above. Compared with placebo or 20 mg olmesartan, LCZ696 showed no superiority in terms of reducing adverse events or serious adverse events.ConclusionsLCZ696 at 200 mg or 400 mg was better at reducing most of blood pressure parameters than 20 mg olmesartan or placebo. Compared with placebo or 20 mg olmesartan, 200 mg or 400 mg LCZ696 do not result in more adverse events in treating hypertension.

Highlights

Hypertension is one of the most common cardiovascular diseases [1]
Compared with 20mg olmesartan, 200mg and 400mg LCZ696 was better than olmesartan in terms of reducing mean sitting pulse pressure
These studies showed that 400mg LCZ696 was better than 20mg olmesartan in terms of reducing mean ambulatory pulse pressure, there was no significant difference between 200mg LCZ696 and 20mg olmesartan in terms of redducing mean ambulatory pulse pressure

Summary

Introduction

Hypertension is one of the most common cardiovascular diseases [1]. it can be treated with a variety of drugs, there is ongoing and intensive research to develop drugs that reduce blood pressure (BP) more effectively.A potential antihypertensive drug target that has received considerable interest over the years is neprilysin. Since NPs can increase natriuresis and diuresis, they can lower BP They directly regulate the reninangiotensin-aldosterone system (RAAS): they can reduce renin release, which in turn decreases the secretion of angiotensin II and aldosterone [3]. The neprilysin inhibitors ecadotril, racecadotril, and candoxatril fail to treat heart disease and hypertension effectively [7,8,9], many clinical studies have shown that omapatrilat, which inhibits various proteases including neprilysin, angiotensin-converting enzyme (ACE), and aminopeptidase, effectively treats hypertension. Such combined therapy may be a potential way to treat hypertension. To determine the effectiveness and safety of LCZ696 for the clinical treatment of hypertension, we performed a meta-analysis of the previous clinical trials

Methods

Results

Conclusion